share_log

Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying

Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying

在這隻通信服務股票上押注約500萬美元?看看內部人士正在買入的這4只股票
Benzinga ·  03/22 19:29

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

儘管週四美國股市收高,但有一些值得注意的內幕交易。

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

當內部人士購買股票時,這表明他們對公司前景充滿信心,或者他們認爲股票很划算。無論哪種方式,這都預示着做多該股的機會。不應將內幕購買視爲做出投資或交易決策的唯一指標。充其量,它可以爲購買決定提供信心。

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

以下是最近一些值得注意的內幕收購。欲了解更多,請查看 本辛加的內幕交易 平台。

Cardlytics

Cardlytics

  • The Trade: Cardlytics, Inc. (NASDAQ:CDLX) 10% owner Clifford Sosin acquired a total of 350,000 shares an average price of $14.16. To acquire these shares, it cost around $4.96 million.
  • What's Happening: On March 18, Cardlytics entered an Equity Distribution Agreement pursuant to which the Company may issue and sell, from time to time up to $50 million.
  • What Cardlytics Does: Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications.
  • 交易:Cardlytics, Inc.(納斯達克股票代碼:CDLX)10% 的所有者克利福德·索辛 共收購了 350,000 股股票 平均價格爲14.16美元。收購這些股票的成本約爲496萬美元。
  • 發生了什麼:3月18日,Cardlytics簽訂了股權分配協議,根據該協議,公司可以不時發行和出售高達5000萬美元的股權。
  • Cardlytics做什麼:Cardlytics Inc在金融機構的數字渠道中運營廣告平台,包括在線、移動、電子郵件和各種實時通知。

Phunware

Phunware

  • The Trade: Phunware, Inc. (NASDAQ:PHUN) CFO Troy Lee Reisner acquired a total of 2,000 shares at an average price of $8.76. To acquire these shares, it cost around $17,514.
  • What's Happening: On March 12, Phunware reported worse-than-expected fourth-quarter EPS results.
  • What Phunware Does: Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences.
  • 交易:Phunware, Inc.(納斯達克股票代碼:PHUN)首席財務官特洛伊·李·雷斯納共收購了2,000股股票,平均價格爲8.76美元。收購這些股票的成本約爲17,514美元。
  • 發生了什麼:3月12日,Phunware公佈的第四季度每股收益業績低於預期。
  • Phunware 做什麼:Phunware Inc 是一家軟件公司。它是一個移動雲平台,爲公司提供吸引、管理移動應用程序受衆並從中獲利所需的產品、解決方案以及數據和服務。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

Energy Services of America

美國能源服務

  • The Trade: Energy Services of America Corporation (NASDAQ:ESOA) Director Mark Prince bought a total of 14,000 shares at an average price of $8.17. To acquire these shares, it cost around $114,860.
  • What's Happening: On March 6, Energy Services of America retained Three Part Advisors as investor relations counsel.
  • What Energy Services of America Does: Energy Services of America Corporation is engaged in providing contracting services for energy-related companies.
  • 貿易:美國能源服務公司(納斯達克股票代碼:ESOA)董事馬克·普林斯 共購買了 14,000 股股票 平均價格爲8.17美元。收購這些股票的成本約爲114,860美元。
  • 發生了什麼:3月6日,美國能源服務公司聘請了由三部分組成的顧問作爲投資者關係顧問。
  • 美國能源服務公司做什麼:美國能源服務公司從事爲能源相關公司提供合同服務。

Entrada Therapeutics

Entrada 療法

  • The Trade: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S Kim bought a total of 2,732 shares at an average price of $12.81. The insider spent around $34,996 to buy those shares.
  • What's Happening: On March 13, Entrada Therapeutics posted upbeat quarterly sales.
  • What Entrada Therapeutics Does: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
  • 交易:Entrada Therapeutics, Inc.(納斯達克股票代碼:TRDA)董事彼得·金 共購買了 2,732 股股票 平均價格爲12.81美元。知情人士花費了約34,996美元購買了這些股票。
  • 發生了什麼:3月13日,Entrada Therapeutics公佈了樂觀的季度銷售額。
  • Entrada Therapeutics的所作所爲:Entrada Therapeutics Inc是一家處於臨床階段的生物製藥公司,旨在通過開發一類新的藥物來改變患者的生活,這些藥物可以利用長期以來被認爲無法獲得的細胞內靶標。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論